The FDA’s fourth BE approach! Yada Yada Yada [Regulatives / Guidelines]

posted by jag009  – NJ, 2015-09-23 22:29 (3926 d 06:32 ago) – Posting: # 15461
Views: 19,336

Hi Helmut,

❝ As if pulling a rabbit out of the hat. László Endrényi regularly goes ballistic on this issue. He showed already twenty years ago (in the context of IBE) that this limit is arbitrary and the “method” flawed.


I was in one local BA/BE meeting last week in NJ. One of the ex-FDA presenter (consultant) made a short "blasting" speech on the Sub*formulation interaction test on Concerta... I wonder when my old prof Laszlo will start his own campaign....

John

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
140 visitors (0 registered, 140 guests [including 35 identified bots]).
Forum time: 05:02 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5